The FDA said it is pushing back against claims that it is increasingly rejecting new drugs after an initial review, arguing that the characterization is inaccurate. The agency’s response follows references to a 2027 budget-related report that suggested a rise in early refusals, with the FDA disputing that trend and its interpretation.